An inhibitor of ACC1 and ACC2
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PF-05221304

Item No. 36856

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-[6-methoxy-4-[[1,4,6,7-tetrahydro-1-(1-methylethyl)-7-oxospiro[5H-indazole-5,4′-piperidin]-1′-yl]carbonyl]-2-pyridinyl]-benzoic acid
CAS Number
1370448-25-1
Synonyms
  • Clesacostat
Molecular Formula
C28H30N4O5
Formula Weight
502.6
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Soluble
λmax
255, 311 nm
SMILES
O=C(C1=CC=C(C2=CC(C(N3CCC4(CC3)CC(C5=C(C4)C=NN5C(C)C)=O)=O)=CC(OC)=N2)C=C1)O
InChi Code
InChI=1S/C28H30N4O5/c1-17(2)32-25-21(16-29-32)14-28(15-23(25)33)8-10-31(11-9-28)26(34)20-12-22(30-24(13-20)37-3)18-4-6-19(7-5-18)27(35)36/h4-7,12-13,16-17H,8-11,14-15H2,1-3H3,(H,35,36)
InChi Key
LXZMHBHEXAELHH-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $90

    Add

    5 mg

    $422

    Add

    10 mg

    $755

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    PF-05221304 is an inhibitor of acetyl-CoA carboxylase 1 (ACC1) and ACC2 (IC50s = 12.4 and 8.7 nM, respectively).1 It inhibits de novo lipid synthesis (IC50 = 61 nM) and increases fatty acid oxidation in primary human hepatocytes. PF-05221304 reduces the accumulation of triglycerides composed of de novo-derived fatty acids but not dietary essential fatty acids in primary human hepatocytes. In vivo, PF-05221304 (10 and 100 mg/kg) reduces hepatic malonyl-CoA production and de novo lipogenesis in rats. It reduces hepatic fibrosis, alanine transaminase (ALT) and aspartate aminotransferase (AST) levels, and triglyceride accumulation in a rat model of non-alcoholic steatohepatitis (NASH) induced by a choline-deficient and high-fat diet (CDAHFD).

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ross, T.T., Crowley, C., Kelly, K.L., et al. Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems. Cell. Mol. Gastroenterol. Hepatol. 10(4), 829-851 (2020).